Olivier Taelman
Chief Executive Officer chez NYXOAH SA
Fortune : 6 M $ au 31/03/2024
Profil
Olivier Taelman is currently the Chief Executive Officer & Executive Director at Nyxoah SA. Prior to his current position, he worked as the Business Director-Neuromodulation at Nevro Corp.
from 2013 to 2015, and as the Vice President-Europe at Autonomic Technologies, Inc. from 2015 to 2019.
Mr. Taelman completed his undergraduate degree at Hasselt University and holds an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NYXOAH SA
1,47% | 18/03/2024 | 419 930 ( 1,47% ) | 6 M $ | 31/03/2024 |
Postes actifs de Olivier Taelman
| Sociétés | Poste | Début |
|---|---|---|
| NYXOAH SA | Chief Executive Officer | 01/11/2019 |
Anciens postes connus de Olivier Taelman
| Sociétés | Poste | Fin |
|---|---|---|
Autonomic Technologies, Inc.
 Autonomic Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | 01/11/2019 |
| NEVRO CORP. | Corporate Officer/Principal | 01/12/2015 |
Formation de Olivier Taelman
| Hasselt University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NEVRO CORP. | Health Technology |
| NYXOAH SA | Health Technology |
| Entreprise privées | 1 |
|---|---|
Autonomic Technologies, Inc.
Autonomic Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA. | Electronic Technology |
